The Harmonie trial shows a hospitalisation benefit where Melody could not.
SRP-9001 heads for its month of regulatory probing, as vaccines from GSK and Pfizer, and Genmab and Abbvie’s bispecific, await FDA approval decisions.
The second quarter promises big data reveals for Fibrogen, Travere, Argenx and Bavarian Nordic.
US experts favour GSK’s RSV vaccine over Pfizer’s, but both could be on the market soon.
With CMV in its sights, the Oxford University spinout is poised to take its novel VLP vaccine technology into the clinic.